AFSC - ETF AI Analysis
Top Page
abrdn Focused U.S. Small Cap Active ETF (AFSC)
Rating:65Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and over the last few months, indicating positive recent momentum in its strategy.
Solid Top Holdings Contribution
Most of the largest positions, including companies in restaurants, pharmaceuticals, software, and regional banks, have delivered strong year-to-date results that support the fund’s overall performance.
Diversified Sector Mix Within Small Caps
Holdings are spread across several sectors such as health care, financials, technology, industrials, and consumer-focused companies, which helps reduce the impact of weakness in any single industry.
Negative Factors
Higher-Than-Average Expense Ratio
The fund’s fee is relatively high for an ETF, which can eat into returns over time compared with lower-cost options.
Single-Country Concentration
With almost all assets invested in U.S. companies, the ETF offers little geographic diversification and is heavily tied to the U.S. economy.
Small-Cap and Stock-Specific Risk
The focus on U.S. small-cap stocks and meaningful weights in individual names, including at least one lagging top holding, can make the fund more volatile and sensitive to company-specific setbacks.
AFSC vs. SPDR S&P 500 ETF (SPY)
AUM9.68M
RegionNorth America
Expense Ratio0.65%
Beta0.80
Issueraberdeen
Inception DateFeb 18, 2025
Dividend Yield0.06%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume438
30 Day Avg. Volume444
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
48.03Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering40
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AFSC Summary
AFSC is the abrdn Focused U.S. Small Cap Active ETF, which invests in a handpicked group of smaller U.S. companies instead of tracking a fixed index. It spreads money across areas like health care, financials, technology, and industrials, with holdings such as Brinker International and Merit Medical Systems. Investors might consider AFSC if they want growth potential from smaller, up‑and‑coming businesses and added diversification beyond large, well-known stocks. However, because it focuses on small companies and is actively managed, its price can be more volatile and can go up and down more sharply than the overall market.
How much will it cost me?The abrdn Focused U.S. Small Cap Active ETF (AFSC) has an expense ratio of 0.65%, which means you’ll pay $6.50 per year for every $1,000 invested. This is higher than the average for ETFs because it is actively managed, meaning professional managers are selecting investments rather than following a passive index.
What would affect this ETF?The abrdn Focused U.S. Small Cap Active ETF (AFSC) could benefit from strong growth in the U.S. economy, particularly in sectors like technology and healthcare, which are heavily weighted in the fund. However, small-cap stocks are often more sensitive to rising interest rates and economic slowdowns, which could negatively impact their performance. Regulatory changes or sector-specific challenges in industries like financials or consumer cyclical could also pose risks to this ETF's future returns.
AFSC Top 10 Holdings
AFSC leans heavily into U.S. small-cap health care, with names like Kiniksa Pharmaceuticals and Ligand Pharma doing much of the heavy lifting as their shares have been rising and adding energy to the fund. Brinker International has also been a bright spot, giving the consumer side some punch. On the flip side, Magnolia Oil & Gas and Supernus Pharmaceuticals have been lagging, acting like a bit of sand in the gears. Overall, the ETF is firmly U.S.-focused, with performance driven by a concentrated mix of small-cap health care and select consumer and energy plays.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals | 3.31% | $322.24K | $5.91B | 96.91% | 72 Outperform | |
| Merit Medical Systems | 3.29% | $320.31K | $5.10B | 1.38% | 68 Neutral | |
| American Healthcare REIT, Inc. | 3.26% | $317.17K | $11.14B | 24.08% | 64 Neutral | |
| Quaker Chemical | 3.19% | $309.97K | $2.77B | 19.91% | 58 Neutral | |
| Ligand Pharma | 3.01% | $292.45K | $6.04B | 67.39% | 60 Neutral | |
| Magnolia Oil & Gas | 2.91% | $283.11K | $5.70B | 1.82% | 65 Neutral | |
| Seacoast Banking Of Florida | 2.86% | $278.34K | $3.16B | 5.69% | 62 Neutral | |
| Supernus Pharmaceuticals | 2.81% | $273.54K | $2.47B | -12.35% | 55 Neutral | |
| Ameris Bancorp | 2.72% | $264.07K | $5.47B | 10.37% | 78 Outperform | |
| StoneX Group | 2.69% | $261.86K | $7.94B | 46.53% | 58 Neutral |
AFSC Technical Analysis
Neutral
―
Price Trends
38.00
Negative
37.51
Negative
34.93
Positive
Market Momentum
-0.30
Negative
51.24
Neutral
89.98
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For AFSC, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 37.02, equal to the 50-day MA of 38.00, and equal to the 200-day MA of 34.93, indicating a neutral trend. The MACD of -0.30 indicates Negative momentum. The RSI at 51.24 is Neutral, neither overbought nor oversold. The STOCH value of 89.98 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AFSC.
AFSC Peer Comparison
Comparison Results
Performance Comparison
AFSC
abrdn Focused U.S. Small Cap Active ETF
37.36
7.21
23.91%
AIMS
Acuitas Small Cap Active ETF
―
―
―
RUSC
US Small Cap Equity Active ETF
―
―
―
SYZ
Lazard US Systematic Small Cap Equity ETF
―
―
―
ESSC
Eventide Small Cap ETF
―
―
―
FTKI
First Trust Small Cap BuyWrite Income ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents